Summary
Twenty-nine previously untreated patients with head and neck carcinoma received a total of 63 cycles of an initial chemotherapy protocol combining cis-platinum (100 mg/m2 on day 1) and continuous 5-day infusion of 5-FU (1000 mg/m2/24 h) from day 2 to day 6. This protocol was repeated on day 16 and day 31. Two daily blood samples obtained from all patients every day during 5-FU administration were analyzed by HPLC to determine the 5-FU concentrations. In the majority of cases a constant elevation was observed in total 5-FU cycle exposure (CxT) from cycle to cycle. A close relationship was demonstrated between elevated 5-FU CxT values (over 30 000 ng h ml-1) and the frequency of cycles in which signs of toxicity (myelosuppression, mucositis, diarrhea) were observed. By contrast, no obvious association was noted between response to treatment and systemic 5-FU exposure.
Similar content being viewed by others
References
Au JLS, Rustum YM, Ledesma EJ, Mittelman A, Creaven RJ (1982) Clinical pharmacological studies of concurrent infusion of 5-fluorouracil, and thymidine in treatment of colorectal carcinomas. Cancer Res 42: 2930
Balis FM, Holcenberg JS, Bleyer WA (1983) Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 8: 202
Christophidis N, Mihaly G, Vajda F, Louis W (1979) Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin Chem 25: 83
Davis HL (1982) Chemotherapy of large bowel cancer. Cancer 50: 2638
Ervin TJ, and Weichselbaum RR (1983) Chemotherapy of squamous carcinoma of the head and neck, In: Bertino JR (ed) The chemotherapy of breast, gastrointestinal and head and neck cancer. Pharmalibri, Chicago, p 60
Fraile JR, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK (1980) Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40: 2223
Hillcoat BL, McCullogh PB, Figueredo AT, Ehsan MH, Rosenfeld JM (1978) Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 38: 719
Kirkwood JM, Ensminger W, Rosowsky A, Papathanasopoulos N, Frei E III (1980) Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouacil with concurrent thymidine infusions in a phase I trial. Cancer Res 40: 107
Kish J, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh J, Weaver A, Al-Sarraf M (1982) Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 66: 471
Myers CE (1981) The pharmacology of the fluoropyrimidines. Pharmacol Rev 33: 1
Schuetz JD, Wallace HJ, Diasio RB (1984) 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 44: 1358
Seitz JF, Cano JP, Prigault JP, Aubert C, Carcassonne Y (1983) Chimiothérapic des cancers digestifs étendus par le 5-Fluoro-uracile: relations entre la réponse clinique et la clairance plasmatique du médicament. Gastroenterol Clin Biol 7: 374
Tognoni G, Bellantuono C, Bonati M, D'Incalci M, Gerna M, Latini R, Mardelli M, Porro MG, Riva E (1980) Clinical relevance of pharmacokinetics. Clin Pharmacokinet 5: 105–136
Yee GC, Crom WR, Champion JE, Brodeur GM, Evans WE (1983) Cisplatin-induced changes in bleomycin elimination. Cancer Treat Rep 67: 587
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thyss, A., Milano, G., Renée, N. et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother. Pharmacol. 16, 64–66 (1986). https://doi.org/10.1007/BF00255288
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255288